A biopharmaceutical firm based in Rehovot, Israel has been awarded the Genesis Prize Foundation (GPF) Start-Up Nation Central (SNC) for its work in the fight against coronavirus and future pandemics.
The firm – Kamada Ltd. – was awarded the prize for its creation of a plasma derived immunoglobulin (IgG) product which can be used in the treatment against COVID-19. In addition, Kamada received the prize as the product has been recognized as a “promising technology that has the potential to provide significant benefits in the near future.”
According to Amir London, the firm’s CEO:
“We are deeply honored to receive this prestigious award from the GPF and SNC and for being recognized for the development of our plasma-derived IgG product against COVID-19. As previously reported, we executed an agreement with the Israeli Ministry of Health (“IMOH”) to supply our product for the treatment of COVID-19 patients in Israel, under which the initial supply is expected to generate approximately $3.4 million in revenues during the first quarter of 2021. Importantly, per recent discussions with the IMOH, the treatment utilizing our product will be provided as part of a multi-center clinical study led by the IMOH.”